Biostimulatory Fillers: Types, Product Roles and Clinic Selection

Q: How long do biostimulatory fillers last?

A practical planning range is around 12 to 24 months across the major material families, with meaningful product-level differences. CaHA can show an immediate carrier-based effect, while the collagen-related phase of PLLA, PDLLA, PCL, and CaHA is generally discussed over the following one to three months. Individual duration varies.

Reviewed against current manufacturer information, public regulator records, peer-reviewed reviews, and the current FillersFairy product listings. Last source review: July 28, 2026.

Quick Answer: Biostimulatory fillers are injectable products selected not only for the space they occupy, but also for the tissue-remodelling response they are intended to support. The practical clinic decision is whether the consultation needs a gradual powder-based volume programme, a PDLLA-plus-HA product family, a ready-to-use liquid PCL route, or CaHA that combines immediate contour support with longer-term biostimulation. In this guide, Sculptra, AestheFill, Juvelook, Gouri, Radiesse, and Volassom each have a distinct, positive inventory role.

Six Clinic Demands, Six Product Roles

Consultation or inventory demand	Product route	Why that route is useful	What the clinic should explain
Recognised PLLA programme for broad, gradual facial restoration	Sculptra	A globally recognised PLLA name, a documented product history, and a two-vial FillersFairy pack	The change develops gradually; it is not an instant, precisely placed HA-style correction.
Korean PDLLA programme centred on a single 200 mg vial	AestheFill	A distinct PDLLA-only route for clinics building a Korean collagen-stimulator menu without adding HA to the product formula	Its commercial role is a PDLLA facial volume and contour programme, supported by the exact local product documents.
One brand family spanning lighter skin-quality and fuller volume conversations	Juvelook 50 mg / Juvelook 200 mg	PDLLA plus non-crosslinked HA in two stocked strengths creates a clear family-level consultation pathway	The exact strength and documented use must be chosen before the product is presented as a “Juvelook treatment.”
Ready-to-use liquid PCL route with no powder reconstitution	Gouri	A one-syringe liquid PCL format for clinics that want a whole-face collagen-support conversation rather than another powder vial	Explain it as a gradual tissue-quality route with its own liquid-PCL consultation language.
CaHA route combining visible contour support with biostimulation	Radiesse	A well-documented CaHA product in a single 1.5 mL syringe, suited to clinics with an established CaHA service language	The gel-carrier effect is immediate, while collagen-related change develops over time.
Korean CaHA route with two smaller syringes in one box	Volassom	A 2 × 0.8 mL format that supports modular stock planning and a Korean CaHA menu, backed by product-specific midface research	Its distinct role comes from its Korean brand system, product evidence, and dual-syringe pack format.

The routing principle is simple: define the patient demand and the clinic’s service menu first, then choose the material family, product documents, brand system, and pack. This prevents six products from being presented as interchangeable boxes of “collagen filler.”

Biostimulatory Fillers clinic buyer’s guide featuring a natural woman and PLLA, PDLLA, PCL and CaHA

What Makes Biostimulatory Fillers Different?

A conventional hyaluronic-acid filler is usually selected for the volume, shape, hydration, or tissue integration created by the gel itself. A biostimulatory filler adds another objective: the material is intended to trigger a controlled tissue response that supports new extracellular-matrix production, including collagen. That does not mean every product works at the same speed or creates the same visual direction.

PLLA and PDLLA products are commonly supplied as lyophilised powders that require preparation before professional use. Their selling story is therefore a gradual programme. PCL can appear in different forms; the Gouri SKU in this guide is a ready-to-use liquid product and belongs to a different stock and consultation route. CaHA products are supplied in pre-filled gel syringes, so they can provide an immediate contour component while the tissue-remodelling phase continues.

“Biostimulatory” also does not mean “permanent.” The materials are designed to degrade, while the clinical change and newly formed tissue can persist beyond the carrier or particle phase. Published reviews repeatedly note that evidence quality, outcome measures, follow-up length, and product formulations differ. A clinic should therefore use material-level timelines for consultation planning and exact-product data when making a product-specific claim.

PLLA, PDLLA, PCL and CaHA: A Material-First Decision Map

Choosing among biostimulatory fillers begins with the material pathway, because a powder-based gradual-volume programme, a liquid PCL route, and a ready-to-use CaHA syringe create different patient expectations and inventory workflows.

For a material-by-material explanation before product selection, read Collagen Stimulators Explained: PLLA, PDLLA, PCL and CaHA.

Material	Typical stocked form in this guide	Immediate visual component	When gradual change is usually discussed	Practical duration planning range	Reversibility boundary	Representative products
PLLA	Lyophilised powder in vials	Early change may partly reflect the prepared suspension; the intended restoration builds gradually.	About 1–3 months, with continued development across the treatment plan	Often around 18–24 months in product and clinical follow-up; individual response varies	Not dissolved with hyaluronidase	Sculptra
PDLLA	Lyophilised powder; PDLLA-only or PDLLA + non-crosslinked HA	Depends on the exact formula and carrier; the collagen-related phase remains gradual.	About 1–3 months, with product-specific differences	Commonly discussed around 12–24 months, but the exact product evidence controls the claim	HA in a hybrid product does not make the PDLLA component fully reversible	AestheFill; Juvelook 50 mg and 200 mg
PCL	Ready-to-use liquid PCL in a pre-filled syringe for the Gouri route	Do not assume an HA-like projection effect; visual direction depends on the exact PCL formulation.	About 1–3 months for progressive collagen-related change	About 12–24 months in the broader PCL literature; this is not a guarantee for every PCL SKU	Not dissolved with hyaluronidase	Gouri
CaHA	Ready-to-use microspheres suspended in a gel carrier	Visible immediately from the carrier and structural gel component	About 1–3 months for the remodelling phase	Often around 12–24 months; Radiesse reports results up to two years, while Volassom has product-specific 24-week clinical data	Not dissolved with hyaluronidase	Radiesse; Volassom

These ranges give the patient real numbers without pretending every face or SKU behaves identically. Age, tissue quality, treatment area, baseline volume loss, metabolism, product choice, and the completed treatment plan can all move the timeline. Clinics should state the range first, then document the exact product evidence used in the consultation.

Six Product and Inventory Routes

Clinics comparing biostimulatory fillers can use the matrix below to separate regulatory indications, manufacturer positioning, clinical literature, and FillersFairy pack facts. A commercial role is not rewritten as a regulatory indication, and evidence from one brand is not transferred to another product simply because they share a material.

Exact SKU	Material and form	Best-fit patient demand	Expected visual direction	Clinic inventory role	Pack format	Evidence type	Relevant destination-market check	What makes it different from the other five
Sculptra (2 Vials)	PLLA microparticles with CMC and mannitol; lyophilised powder	Broad, gradual facial restoration and patients who ask for Sculptra or an established PLLA name	Progressive restoration of depleted-looking volume and softer facial transitions	Recognised international PLLA programme and two-vial stock route	Current FillersFairy listing: 2 lyophilised vials	Documented regulatory/clinical evidence for exact labelled versions; manufacturer product history; FillersFairy pack fact	Match the supplied two-vial presentation, label, IFU, and authorised uses to the destination market.	The only PLLA product in this six-role matrix and the only internationally recognised gradual-volume route supplied as two vials.
AestheFill 200 mg	PDLLA porous microspheres in a CMC carrier; lyophilised powder	A Korean PDLLA route for gradual volume and contour conversations without an HA component in the listed formula	Gradual facial restoration with a natural, programme-based direction	Single-vial Korean PDLLA programme and REGEN Biotech brand-family route	Current FillersFairy listing: 1 × 200 mg vial	Manufacturer-positioned role; Class III TGA device record for AestheFill-V200; product-specific and PDLLA literature; FillersFairy pack fact	Verify the exact AestheFill-V200 certificate, labelling, authorised purpose, and professional-use documents accepted at the destination.	The PDLLA-only 200 mg route; it does not duplicate Juvelook’s PDLLA-plus-HA family or Sculptra’s PLLA brand system.
Juvelook 50 mg / Juvelook 200 mg	PDLLA + non-crosslinked HA; lyophilised hybrid formula	Clinics that want one family for lighter skin-quality demand and a separate higher-content volume route	From refined skin-quality support to fuller soft-tissue restoration, depending on the exact SKU and consultation	Two-level PDLLA + HA menu with clear strength-based stock separation	Current FillersFairy listings: 1 × 50 mg vial or 1 × 200 mg vial	Documented Korean product purpose and composition; Class III TGA device record; manufacturer line positioning; FillersFairy SKU facts	Match the 50 mg or 200 mg presentation to its own label and destination documents; do not treat the two strengths as one interchangeable SKU.	The only hybrid PDLLA + HA family here, with two stocked strengths that can support separate consultation routes.
Gouri Liquid PCL 1 mL	Ready-to-use liquid PCL; FillersFairy lists 210 mg/mL in a particle-free solution	A whole-face collagen-support conversation and clinics preferring a liquid syringe rather than another reconstituted powder	Gradual improvement in firmness and tissue quality without positioning the product as a high-projection gel	Ready-to-use PCL menu and compact one-syringe inventory route	Current FillersFairy listing: 1 × 1 mL pre-filled syringe	Manufacturer-positioned liquid-PCL role; active Class III TGA device record naming DEXLEVO; emerging PCL clinical literature; FillersFairy pack fact	Confirm the exact Gouri product record, IFU, certificate, and authorised professional use for the destination market.	The only ready-to-use liquid PCL product in the matrix and the only single 1 mL syringe centred on a liquid collagen-stimulator menu.
Radiesse 1 × 1.5 mL	Approximately 30% CaHA microspheres in a CMC-based gel carrier; pre-filled syringe	Patients asking for visible contour support now plus an established CaHA biostimulation story	Immediate structure and definition, followed by progressive tissue-quality support	Recognised international CaHA programme and single 1.5 mL syringe route	Current FillersFairy listing: 1 × 1.5 mL pre-filled syringe	Documented regulatory/clinical evidence for exact versions and indications; current manufacturer composition and duration information; FillersFairy pack fact	Match the supplied Radiesse presentation—standard or lidocaine version where relevant—to the exact destination-market label and indication.	The established 1.5 mL CaHA route, distinct from Volassom’s Korean two-syringe inventory format.
Volassom 2 × 0.8 mL	Approximately 30% CaHA microspheres in a CMC, glycerin, and water gel carrier; pre-filled syringes	Clinics building a Korean CaHA service and wanting two smaller syringes for modular stock planning	Immediate midface or contour support plus gradual firmness and skin-quality improvement	Korean CaHA programme, product-specific midface evidence, and dual-syringe stock route	Current FillersFairy listing: 2 × 0.8 mL pre-filled syringes	Manufacturer-positioned role; 2025 prospective product-specific study with 24-week follow-up; FillersFairy pack fact	Verify the exact Volassom label, certificate, authorised purpose, and CGBio product documents required by the destination.	The Korean 2 × 0.8 mL CaHA route, supported by its own midface study and a distinct dual-syringe inventory format.

Which Biostimulatory Filler Should a Clinic Start With?

For a new clinic, the first decision does not need to be a six-product decision. Start with the business model the clinic can already sell: a gradual collagen-restoration programme, an immediate contour service, a Korean regenerative line, a ready-to-use workflow, or a broader anti-ageing menu. The table below turns each model into a practical first order.

Business case	Start with	Choose this route when	Commercial next step
Case 1: the clinic is entering collagen stimulators for the first time	Sculptra or Radiesse	Choose Sculptra when patients recognise the brand, the clinic wants a long-term gradual-restoration programme, and consultations can support progressive change. Choose Radiesse when patients want visible contour support now and the clinic already sells contour or deep-fold services.	Add the other product when demand is strong enough to separate gradual volume restoration from immediate contour support.
Case 2: the clinic already sells Korean aesthetic products	AestheFill or Juvelook	Choose AestheFill for a focused PDLLA-only 200 mg programme. Choose Juvelook when the clinic wants one PDLLA + HA family that can connect skin-quality demand with a separate higher-content volume route.	Add Volassom when the Korean menu also needs CaHA contour support and a 2 × 0.8 mL stock format.
Case 3: the clinic does not want a powder-reconstitution workflow	Gouri, Radiesse, or Volassom	Choose Gouri for a ready-to-use liquid PCL and whole-face tissue-quality route; Radiesse for a recognised 1.5 mL CaHA contour route; or Volassom for Korean CaHA with two 0.8 mL syringes.	Add a powder-based product later only when the clinic is ready to sell a distinct gradual-volume programme.
Case 4: the clinic is building a high-end anti-ageing menu	Sculptra + Radiesse + Juvelook	The three roles cover gradual broad volume restoration, immediate contour support, and a skin-quality-to-volume PDLLA + HA family.	Expand with AestheFill, Gouri, or Volassom when Korean PDLLA, liquid PCL, or Korean dual-syringe CaHA demand becomes visible in consultations.

Biostimulatory Filler Service-Menu Stock Combinations

Once the first route is selling consistently, the clinic can expand by menu rather than adding isolated boxes. Each combination below gives staff a clear reason to carry every included SKU.

Service menu	Stock combination	What the menu can sell	Expansion trigger
Starter Biostimulator Menu	Radiesse + Juvelook	Radiesse gives the clinic an immediate contour-and-biostimulation route; the Juvelook family adds skin-quality demand and a separate volume conversation.	Add Sculptra when patients begin asking for a recognised gradual PLLA programme.
Korean Regenerative Menu	AestheFill + Juvelook + Volassom	The combination covers PDLLA-only, PDLLA + HA, and CaHA, with separate gradual-volume, skin-quality, and immediate-contour conversations.	Add Gouri when the clinic sees demand for a ready-to-use liquid PCL and whole-face tissue-quality route.
Premium International Menu	Sculptra + Radiesse	Two internationally recognised names give the clinic a gradual PLLA restoration programme and an immediate-plus-gradual CaHA contour programme.	Add Juvelook when a distinct skin-quality entry service and PDLLA + HA family will broaden the consultation.
Full Regenerative Menu	Sculptra + AestheFill + Juvelook + Gouri + Radiesse + Volassom	The full menu covers PLLA, PDLLA-only, PDLLA + HA, liquid PCL, international CaHA, and Korean dual-syringe CaHA without presenting them as interchangeable products.	Use the full menu when consultation demand and stock turnover can support every defined role.

The practical starting point: a clinic new to the category can begin with one core route, while a clinic that wants broader conversion coverage can begin with the Radiesse + Juvelook starter combination. The full six-role menu becomes useful only when the team can name the consultation demand, visual direction, and turnover expectation attached to every SKU.

Evidence and Destination-Market Boundaries

Use four labels consistently. A documented indication belongs to a specific product version and jurisdiction. A manufacturer-positioned role describes how the product company presents its technology or family. Clinical evidence belongs to the exact product or material studied, with its own sample size and follow-up. A FillersFairy inventory fact supports the current pack, strength, and product-page information.

Before procurement, match the exact SKU to its manufacturer, label, certificate or registration record, instructions for use, lot and expiry information, and the rules of the destination market. This keeps product claims accurate for global clinic buyers and prevents a documented use for one version, one concentration, or one brand from being transferred to another.

Biostimulatory Filler Safety

Biostimulatory products should be selected and administered only by appropriately qualified professionals who understand facial anatomy, the exact material, product preparation requirements, and complication management. Common early reactions across injectable fillers include swelling, redness, tenderness, and bruising. Delayed nodules, inflammatory reactions, infection, and granuloma are documented possibilities, while unintended vascular injection can cause rare but serious injury.

These products are not equivalent to a reversible HA-only plan. Hyaluronidase does not dissolve PLLA, PDLLA, PCL, or CaHA; the HA component of a hybrid formula does not make the entire product reversible. A patient with an unknown previous filler, active infection, unexplained persistent nodule, suspected migration, or unresolved inflammatory reaction needs clinical assessment before another product is added. Unusual severe pain, skin blanching or grey-blue colour change, visual symptoms, or neurological symptoms require immediate emergency evaluation.

Frequently Asked Questions

Table of Contents

What are biostimulatory fillers?

They are injectable products selected partly for their ability to support a tissue-remodelling response, including new collagen production. PLLA, PDLLA, PCL, and CaHA are four important material families, but their forms, timelines, visual roles, and evidence are not interchangeable.

How long do biostimulatory fillers last?

A practical planning range is around 12 to 24 months across the major material families, with meaningful product-level differences. CaHA can show an immediate carrier-based effect, while the collagen-related phase of PLLA, PDLLA, PCL, and CaHA is generally discussed over the following one to three months. Individual duration varies.

Can biostimulatory fillers be dissolved?

PLLA, PDLLA, PCL, and CaHA are not dissolved by hyaluronidase. A PDLLA + HA hybrid may contain an HA component, but that does not make the complete product or its collagen response immediately reversible.

Which inventory role matches the clinic’s patient demand?

Choose Sculptra for a recognised gradual PLLA programme; AestheFill for a Korean PDLLA-only 200 mg route; Juvelook for a two-strength PDLLA + HA family; Gouri for ready-to-use liquid PCL; Radiesse for an established 1.5 mL CaHA route; or Volassom for Korean CaHA and a 2 × 0.8 mL pack.

Can a clinic stock all six products?

Yes, when each SKU has a defined role in the consultation and service menu. The objective is not to rank the brands from high to low, but to prevent six different product routes from being presented as interchangeable biostimulatory fillers.

Build a Biostimulatory Filler Menu by Role

Start with the demand already visible in consultations: gradual restoration, skin-quality refinement, ready-to-use workflow, immediate contour support, a named international brand, a Korean brand family, or a particular pack format. Then assign one SKU to that role and add a second product only when it solves a different patient or inventory need.

Explore the current PLLA, PDLLA, PCL and CaHA collection, compare AestheFill and Radiesse, or move directly to the protected Juvelook guide and Volassom guide.

Purchasing conclusion: A clinic can stock all six products when each SKU has a defined role in the consultation and treatment menu. A smaller clinic can start with one evidence-matched route and expand as patient demand and stock turnover justify it. The goal is not to select a universal winner; it is to make every purchased product easier to explain, prescribe, and manage as inventory.